Eversept Partners LP Takes Position in Biohaven Ltd. $BHVN

Eversept Partners LP purchased a new stake in Biohaven Ltd. (NYSE:BHVN) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 145,431 shares of the company’s stock, valued at approximately $1,642,000. Eversept Partners LP owned 0.14% of Biohaven at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. PNC Financial Services Group Inc. increased its holdings in Biohaven by 113.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock valued at $36,000 after buying an additional 1,268 shares during the period. IFP Advisors Inc boosted its stake in Biohaven by 55.4% in the 4th quarter. IFP Advisors Inc now owns 4,069 shares of the company’s stock valued at $46,000 after buying an additional 1,450 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Biohaven by 178.4% in the 4th quarter. EverSource Wealth Advisors LLC now owns 4,031 shares of the company’s stock valued at $46,000 after buying an additional 2,583 shares in the last quarter. Arax Advisory Partners boosted its stake in Biohaven by 943.3% in the 4th quarter. Arax Advisory Partners now owns 4,914 shares of the company’s stock valued at $55,000 after buying an additional 4,443 shares in the last quarter. Finally, Leonteq Securities AG acquired a new stake in Biohaven in the 4th quarter valued at $78,000. Institutional investors own 88.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on BHVN. Wall Street Zen lowered Biohaven from a “sell” rating to a “strong sell” rating in a research note on Sunday, April 26th. Morgan Stanley decreased their price target on Biohaven from $21.00 to $18.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 13th. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Biohaven in a research note on Wednesday, May 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biohaven in a research note on Tuesday, June 2nd. Finally, TD Cowen lifted their target price on shares of Biohaven from $15.00 to $30.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $22.27.

Biohaven Trading Up 13.2%

BHVN opened at $13.69 on Thursday. The company has a current ratio of 7.41, a quick ratio of 7.41 and a debt-to-equity ratio of 1.87. The stock has a market capitalization of $2.06 billion, a PE ratio of -2.41 and a beta of 1.35. Biohaven Ltd. has a 1-year low of $7.48 and a 1-year high of $18.57. The firm has a 50-day moving average price of $10.18 and a two-hundred day moving average price of $10.57.

Biohaven (NYSE:BHVN) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). As a group, equities analysts anticipate that Biohaven Ltd. will post -3.07 earnings per share for the current fiscal year.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.